Search Results - TherapeuticArea+%3e+Neurology

123 Results

Sort By:

Zip14-AAV Genetic MRI Reporter System for Non-Invasive Cell & Gene-Therapy Tracking

This technology includes a gene-based magnetic resonance imaging (MRI) reporter platform that harnesses adeno-associated virus (AAV) delivery of the metal transporter Zip14 to create image contrast wherever the gene is expressed. By driving Zip14 from cell-specific promoters, investigators obtain robust, long-lasting signal changes on standard clinical...

Published: 6/18/2025 | Inventor(s): Harikrishna (Hari) Rallapalli, Alan Koretsky, Raymond (Ray) Fields

Keywords(s):

Category(s): Application > Diagnostics, Application > Therapeutics, TherapeuticArea > Neurology, TherapeuticArea > Radiology, Collaboration Sought > Licensing

Angubindin-1 Peptide for Transient Blood-Brain Barrier Opening to Boost Chemotherapy in Malignant Glioma

This technology includes a first-in-class synthetic peptide, angubindin-1, designed to temporarily relax the blood-brain barrier (BBB)—the tightly sealed network of brain blood vessel cells that normally blocks most drugs—from the inside. By binding the tricellular tight-junction protein angulin-1/LSR, the peptide creates a reversible “molecular...

Published: 6/13/2025 | Inventor(s): Sadhana Jackson

Keywords(s):

Category(s): Application > Therapeutics, TherapeuticArea > Neurology, TherapeuticArea > Oncology, Collaboration Sought > Licensing

Oral Iron-Chelator Therapy for Treating Developmental Stuttering

This technology discloses the use of small-molecule iron chelators—drugs that bind and remove excess iron—for the oral treatment of developmental stuttering in children and adults. Mouse models carrying human stuttering mutations show both elevated striatal iron and impaired vocalization; daily low-dose deferiprone reverses these speech-like...

Published: 6/13/2025 | Inventor(s): Shahriar SheikhBahaei

Keywords(s):

Category(s): Application > Therapeutics, TherapeuticArea > Neurology, TherapeuticArea > Psychiatry/Mental Health, Collaboration Sought > Licensing

Discovery of potent and selective D3 antagonist with alleviated hERG liability and optimized pharmacokinetic properties

One of the most challenging hurdles in creating safe and effective new medicines for many diseases is finding drugs that are effective without causing off-target cardiac issues, such as cardiac arrythmias. In collaboration with NIDA, scientists at NCATS have developed a series of novel and highly specific dopamine D3 receptor agonists and antagonists...

Published: 6/13/2025 | Inventor(s): Khalida Shamim, Wenwei Huang, Wei Zheng, Catherine Chen, Xiuli Huang, Xin Hu, Xin Xu, Pranav Shah, Elias Padilha, Philip Sanderson, Amy Newman

Keywords(s):

Category(s): Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Materials Available, TherapeuticArea > Neurology, TherapeuticArea > Psychiatry/Mental Health

P2Y14 Receptor Antagonists for the Treatment of Inflammatory Diseases, Including Pulmonary and Renal Conditions and Chronic Pain

This technology includes the development of selective P2Y14R antagonists for the treatment of asthma, sterile inflammation of the kidney, diabetes, and neurodegeneration. The P2Y14 receptor (P2Y14R) is a target for the treatment of inflammatory diseases, including pulmonary and renal conditions. Selective P2Y14R antagonists have demonstrated efficacy...

Published: 6/11/2025 | Inventor(s): Young-Hwan Jung, Zhiwei Wen, Kenneth Jacobson

Keywords(s):

Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Endocrinology, TherapeuticArea > Metabolic Disease, TherapeuticArea > Neurology, TherapeuticArea > Pulmonology, TherapeuticArea > Respiratory

Fluorophthalimides as Anti-inflammatory Agents for Systemic and Neurodegenerative Disorder

Summary: The National Institute on Aging (NIA) seeks research co-development partners and/or licensees for the pre-clinical and clinical development of the compounds as anti-inflammatory therapeutics for systemic and neurodegenerative disorders. Description of Technology: Numerous systemic, as well as neurological disorders, have a hallmark inflammatory...

Published: 6/27/2025 | Inventor(s): Nigel Greig, Weiming Luo, David Tweedie, Michael Scerba, Daniela Lecca, Shih Chang Hsueh

Keywords(s):

Category(s): TherapeuticArea > Neurology, TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics

4-Amino-2-(piperidin-3-yl)isoindoline-1,3-diones as Anti-inflammatory Agents for Systemic Degenerative and Neurodegenerative Disorders

Summary: The National Institute on Aging (NIA) seeks research co-development partners and/or licensees for the pre-clinical and clinical development of the compounds as anti-inflammatory therapeutics for systemic degenerative and neurodegenerative disorders. Description of Technology: The immunomodulatory imide drugs (IMiDs) thalidomide and its close...

Published: 6/27/2025 | Inventor(s): Nigel Greig, Michael Scerba, David Tweedie

Keywords(s):

Category(s): TherapeuticArea > Geriatrics, TherapeuticArea > Neurology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing

Margaric Acid Decreases PIEZO2 Mediated Pain

Abstract: Some existing therapies for treatment of pain are administered systematically and have significant side effects, such as addiction and drowsiness. Alternative therapy that does not impair normal touch function could be used to treat pain caused by mechanical injury or chronic inflammation. Administration of margaric acid was shown to ameliorate...

Published: 4/22/2025 | Inventor(s): Alexander Chesler, Valeria Vasquez, Julio Cordero-Morales, Luis Romero

Keywords(s): ALLODYNIA, Chesler, Chronic Inflammation, fatty acid, Margaric Acid, migraine, National Center for Complimentary and Integrative Health, NCCIH, Neuropathy, Pain, PIEZO2, Vásquez

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Neurology, Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Dermatology

Fluorinated MU-Opioid Receptor Agonists

Summary: Investigators at the National Institute on Drug Abuse seek co-development partners and/or licensees for collection of mu opioid receptor (MOR) agonists as alternatives for existing compounds. Description of Technology: Although existing opioids are excellent analgesics and useful as positron emission tomography (PET) radiotracers, they come...

Published: 6/10/2025 | Inventor(s): Michael Michaelides, Juan Gomez, Kenner Rice, Agnieszka Sulima, Michael Baumann

Keywords(s):

Category(s): Application, Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Immunology, TherapeuticArea > Neurology, TherapeuticArea > Radiology, Collaboration Sought > Licensing

Suppression Of Uveitis By A STAT3 Single Domain Antibody

Summary: The National Eye Institute seeks research co-development partners and/or licensees for a STAT3 antibody that can suppress uveitis. Description of Technology: Uveitis is caused by inflammation in the eye that causes pain and reduce vision in affected patients. Rates of uveitis in the United States occurs 1 in every 200 people with eye-related...

Published: 4/22/2025 | Inventor(s): Charles Egwuagu, Sunanda Singh

Keywords(s):

Category(s): Application, Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Neurology, TherapeuticArea > Ear, Nose, & Throat, Collaboration Sought > Licensing

1 2 3 4 5 6 7 8 9 10 ...